drugset / Trial / NCT00563368
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
Timeline
- Start
- 2007-12
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Phentermine | Small molecule | 7.5 mg | Oral |
| Comparator | Phentermine | Small molecule | 15 mg | Oral |
| Comparator | Topiramate | Small molecule | 46 mg | Oral |
| Comparator | Topiramate | Small molecule | 92 mg | Oral |